


Edited by Olivier Gires
and Barbara Seliger

 WILEY-
BLACKWELL

Tumor-Associated Antigens

Identification, Characterization,
and Clinical Applications



Tumor-Associated Antigens

Identification, Characterization, and Clinical
Applications

Edited by
Olivier Gires and Barbara Seliger



**WILEY-
BLACKWELL**

WILEY-VCH Verlag GmbH & Co. KGaA

The Editors

Dr. Olivier Gires

HNO Forschung
Klinikum der Univ.München
Marchioninstr. 15
81377 München

Prof. Dr. Barbara Seliger

MLU Halle-Wittenberg
Institut für Med. Immunologie
Magdeburger Str. 2
06097 Halle

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2009 WILEY-VCH Verlag GmbH & Co. KGaA,
Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Typesetting Thomson Digital, Noida, India

Printing betz-druck GmbH, Darmstadt

Binding Litges & Dopf GmbH, Heppenheim

Cover Design Adam-Design, Weinheim

Printed in the Federal Republic of Germany

Printed on acid-free paper

ISBN: 978-3-527-32084-4

List of Contributors

Patrick A. Baeuerle

Micromet Inc.
Staffelseestr. 2
81477 München
Germany

Uta Behrends

Munich University of Technology
Department of Pediatrics
Kölner Platz 1
80804 München
Germany

and

Institute of Clinical Molecular Biology
and Tumour Genetics
Helmholtz Centre
Marchioninstr. 25
81377 Munich
Germany

Robert J. Binder

University of Pittsburgh Cancer
Institute
Cancer Immunology, Immunotherapy
and Immunoprevention Program
Pittsburgh
PA 15261
USA

Emilio Bombardieri

Fondazione IRCCS
'Istituto Nazionale dei Tumori'
Nuclear Medicine Department
Via Venezian, 1
20133-Milano (I)
Italy

Anthony G. Brickner

University of Pittsburgh Cancer
Institute
Cancer Immunology, Immunotherapy
and Immunoprevention Program
Pittsburgh
PA 15261
USA

Lisa H. Butterfield

University of Pittsburgh Cancer
Institute
Cancer Immunology, Immunotherapy
and Immunoprevention Program
Pittsburgh
PA 15261
USA

Otavia Caballero

Ludwig Institute for Cancer Research
New York Branch of Human Cancer
Immunology
Memorial Sloan-Kettering Cancer
Center
1275 York Avenue, BOX 32
New York, NY 10021-6007 USA

Jonathan Cebon

Ludwig Institute for Cancer Research
Melbourne Centre for Clinical Sciences
Austin Hospital
Studley Road, Heidelberg VIC 3084
Australia

Angela Coliva

Fondazione IRCCS
Istituto Nazionale dei Tumori
Nuclear Medicine Department
Via Venezian, 1
20133-Milano (I)
Italy

John Copier

St George's University of London
Department of Cellular and Molecular
Medicine
Cranmer Terrace
London SW17 0RE
UK

Sandra Coral

Istituto di Ricovero e Cura a Carattere
Scientifico
Centro di Riferimento Oncologico
Cancer Bioimmunotherapy Unit
Department of Medical Oncology
33081 Aviano
Italy

Alessia Covre

Istituto di Ricovero e Cura a Carattere
Scientifico
Centro di Riferimento Oncologico
Cancer Bioimmunotherapy Unit
Department of Medical Oncology
33081 Aviano
Italy

Angus Dalgleish

St George's University of London
Department of Cellular and Molecular
Medicine
Cranmer Terrace
London SW17 0RE
UK

Ferdinand von Eggeling

Universitätsklinikum Jena
Institut für Humangenetik und
Anthropologie
Core Unit Chip Application (CUCA)
Leutragraben 3
07743 Jena
Germany

David P Fairlie

University of Queensland
Centre for Drug Design and
Development
Institute for Molecular Bioscience
Brisbane
Queensland 4072
Australia

Robert L. Ferris

University of Pittsburgh Cancer
Institute
Cancer Immunology, Immunotherapy
and Immunoprevention Program
Pittsburgh
PA 15261
USA

Olivera J. Finn

University of Pittsburgh Cancer
Institute
Cancer Immunology, Immunotherapy
and Immunoprevention Program
Pittsburgh
PA 15261
USA

Ester Fonsatti

University Hospital of Siena
Istituto Toscano Tumori
Division of medical Oncology and
Immunotherapy
Department of Oncology
53100 Siena
Italy

Elisabetta Fratta

Istituto di Ricovero e Cura a Carattere
Scientifico
Centro di Riferimento Oncologico
Cancer Bioimmunotherapy Unit
Department of Medical Oncology
33081 Aviano
Italy

Olivier Gires

LMU Munich
CCG Molecular Oncology
Head and Neck Research Department
Marchioninstr. 15
81377 Munich

and

GSF-National Research Center for
Environment and Health
Marchioninstr. 25
81377 Munich
Germany

Wolfgang Hammerschmidt

German Research Center for
Environmental Health
Helmholtz Center Munich
Department of Gene Vectors
Marchioninstrasse 25
81377 Munich
Germany

Dhiraj Hans

University of Queensland
Centre for Drug Design and
Development
Institute for Molecular Bioscience
Brisbane
Queensland 4072
Australia

Chien-Fu Hung

The John Hopkins Medical Institutions
Departments of Pathology, Obstetrics
and Gynecology, and Oncology
Baltimore
MD 21231
USA

Ping Jin

National Institutes of Health
Infectious Disease and
Immunogenetics Section
Cell Processing Laboratory
Department of Transfusion Medicine
Clinical Center
R-1C711, Bldg 10
9000 Rockville Pike
Bethesda
MD 20892
USA

Thomas John

Ludwig Institute for Cancer Research
Melbourne Centre for Clinical Sciences
Austin Hospital
Studley Road
Heidelberg
VIC 3084
Australia

Pawel Kalinski

University of Pittsburgh Cancer
Institute
Cancer Immunology, Immunotherapy
and Immunoprevention Program
Pittsburgh
PA 15261
USA

Robert Kammerer

Friedrich-Loeffler-Institute (FLI)
Institute of Immunology
Paul-Ehrlich- Str. 28
72076 Tübingen
Germany

Andreas M. Kaufmann

Charité-Universitätsmedizin Berlin
Gynäkologie
Gynäkologische Tumorimmunologie
Campus Benjamin Franklin und
Campus Mitte
Hindenburgdamm 30
12200 Berlin
Germany

Oliver Klein

Ludwig Institute for Cancer Research
Melbourne Centre for Clinical Sciences
Austin Hospital
Studley Road, Heidelberg VIC 3084
Australia

Angela Krackhardt

Institute of Molecular Immunology
Helmholtz-Zentrum München
German Research Center for
Environmental Health
Marchioninstr. 25
81377 München
Germany

Hui Lui Liu

National Institutes of Health
Infectious Disease and
Immunogenetics Section (IDIS)
Department of Transfusion Medicine
Clinical Center
R-1C711, Bldg 10
9000 Rockville Pike
Bethesda
MD 20892
USA

Barbara Ma

The John Hopkins Medical Institutions
Department of Pathology
Baltimore
MD 21231
USA

Michele Maio

University Hospital of Siena
Division of Medical Oncology and
Immunotherapy
Department of Oncology
Strada delle Scotte 14
53100 Siena
Italy

and

Istituto di Ricovero e Cura a Carattere
Scientifico
Centro di Riferimento Oncologico
Cancer Bioimmunotherapy Unit
Department of Medical Oncology
33081 Aviano
Italy

Christoph Mancao

German Research Center for
Environmental Health
Helmholtz Center Munich
Department of Gene Vectors
Marchioninistrasse 25
81377 Munich
Germany

Francesco M. Marincola

National Institutes of Health
Infections Disease and
Immunogenetics Section (IDIS)
Department of Transfusion Medicine
Clinical Center
R-1C711, Bldg 10
9000 Rockville Pike
Bethesda
MD 20892
USA

Josef Mautner

Munich University of Technology
Department of Pediatrics
Kölner Platz 1
80804 Munich
Germany

and

Institute of Clinical Molecular Biology
and Tumour Genetics
Helmholtz Centre Munich
Marchioninistr. 25
81377 Munich
Germany

Christian Melle

Universitätsklinikum Jena
Institut für Humangenetik und
Anthropologie
Core Unit Chip Application (CUCA)
Leutragraben 3
07743 Jena
Germany

Andreas Moosmann

Ludwig-Maximilians-Universität,
Munich
Department of Otorhinolaryngology
Clinical Cooperation Group Molecular
Oncology
Marchioninistr. 25
81377 München
Germany

Frank Neumann

Saarland University Medical School
Med. Klinik und Poliklinik, Innere
Medizin I
66421 Homburg
Germany

Hugues J. M. Nicolay

University Hospital of Siena
Istituto Toscano Tumori
Division of Medical Oncology and
Immunotherapy
Department of Oncology
53100 Siena
Italy

and

Istituto di Ricovero e Cura a Carattere
Scientifico
Centro di Riferimento Oncologico
Cancer Bioimmunotherapy Unit
Department of Medical Oncology
33801 Aviano
Italy

Hideho Okada

University of Pittsburgh Cancer
Institute
Cancer Immunology, Immunotherapy
and Immunoprevention Program
Pittsburgh
PA 15261
USA

Annette Paschen

University Medical School Mannheim
Clinical Cooperation Unit Dermato-
Oncology of the German Cancer
Research Center
Theodor Kutzer Ufer 1
68135 Mannheim
Germany

Michael Pfreundschuh

Saarland University Medical School
Med. Klinik und Poliklinik, Innere
Medizin I
66421 Homburg
Germany

Klaus-Dieter Preuss

Saarland University Medical School
Med. Klinik und Poliklinik, Innere
Medizin I
66421 Homburg
Germany

Gert Riethmueller

Ludwig-Maximilians-University
Institute for Immunology
Goethestr. 31
83333 Munich
Germany

Barbara Seliger

Martin-Luther-Universität Halle-
Wittenberg
Klinikum der Medizinischen Fakultät
Institut für Medizinische Immunologie
Magdeburgerstr. 2
06097 Halle (Saale)
Germany

Ettore Seregni

Fondazione IRCCS
'Istituto Nazionale dei Tumori'
Nuclear Medicine Department
Via Venezian, 1
20133-Milano (I)
Italy

Luca Sigalotti

Istituto di Ricovero e Cura a Carattere
Scientifico
Centro di Riferimento Oncologico
Cancer Bioimmunotherapy Unit
Department of Medical Oncology
33081 Aviano
Italy

Walter J. Storkus

University of Pittsburgh Cancer
Institute
Cancer Immunology, Immunotherapy
and Immunoprevention Program
Pittsburgh
PA 15261
USA

Dourid F. Stroncek

National Institutes of Health
Cell Processing Laboratory
Department of Transfusion Medicine
Clinical Center
R-1C711, Bldg 10
9000 Rockville Pike
Bethesda
MD 20892

Ena Wang

National Institutes of Health
 Infectious Disease and
 Immunogenetics Section (DIS)
 Department of Transfusion Medicine
 Clinical Center
 R-1C711, Bldg 10
 9000 Rockville Pike
 Bethesda
 MD 20892
 USA

Theresa L. Whiteside

University of Pittsburgh Cancer
 Institute
 Cancer Immunology, Immunotherapy
 and Immunoprevention Program
 Pittsburgh
 PA 15261
 USA

T.-C. Wu

The John Hopkins Medical Institutions
 Departments of Pathology, Obstetrics
 and Gynecology, Oncology, and
 Molecular
 Microbiology and Immunology
 Cancer Research Building II,
 Room 309
 1550 Orleans Street
 Baltimore
 MD 21231
 USA

Paul R. Young

University of Queensland
 School of Molecular and Microbial
 Sciences
 Brisbane
 Queensland 4072
 Australia

Hassane M. Zarour

University of Pittsburgh Cancer
 Institute
 Cancer Immunology, Immunotherapy
 and Immunoprevention Program
 Pittsburgh
 PA 15261
 USA

Wolfgang Zimmermann

Ludwig-Maximilian University
 Tumour Immunology Laboratory
 LIFE Center
 University Clinic Grosshadern
 81377 Munich
 Germany

Carsten Zwick

Saarland University Medical School
 Med. Klinik und Poliklinik, Innere
 Medizin I
 66421 Homburg
 Germany

Contents

List of Contributors XV

Part One Tumor-associated Antigens (TAAs): Subclasses of TAAs 1

1 T Cell Antigens in Cancer 3

Annette Paschen

1.1 Introduction 3

1.2 Generation of T-cell Epitopes 4

1.2.1 Subclasses of Tumor-associated T-cell Antigens 5

1.2.1.1 Unique Tumor Antigens 6

1.2.1.2 Cancer Testis Antigens 6

1.2.1.3 Differentiation Antigens 7

1.2.1.4 Overexpressed Antigens 7

1.3 Identification of T-cell Antigens and their Epitopes 8

1.3.1 T-cell Antigens for Cancer Immunotherapy – How are Candidates Selected? 10

1.4 Conclusions 12

References 12

2 Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines 23

Olivera J. Finn, Robert J. Binder, Anthony G. Brickner, Lisa H. Butterfield, Robert L. Ferris, Pawel Kalinski, Hideho Okada, Walter J. Storkus, Theresa L. Whiteside, and Hassane M. Zarour

2.1 Introduction 23

2.2 Tumor Antigen Classes 24

2.2.1 Oncofetal Antigens 24

2.2.2 Oncogenes as Tumor Antigens 25

2.2.3 Overexpressed Normal Molecules as Tumor Antigens 26

2.2.4 Cancer-Testis (CT) Antigens 26

2.2.5	Minor Histocompatibility Antigens (mHAg)s as Tumor Antigens	27
2.2.6	Human Melanoma Antigens	28
2.2.7	Human Glioma Antigens and Immunosurveillance in the CNS	29
2.2.8	Heat Shock Proteins, Efficient Carriers of Tumor Antigens	30
2.2.9	Dendritic Cells, Efficient Cross-presenters of Tumor Antigens	31
2.2.10	Spontaneous and Vaccine-induced Immunity and the Tumor Microenvironment	33
2.3	Summary	34
	References	34

Part Two Methods to Detect TAAs 45

3 Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part I: SEREX 47

Carsten Zwick, Klaus-Dieter Preuss, Frank Neumann, and Michael Pfreundschuh

3.1	Introduction	47
3.2	The SEREX Approach	48
3.2.1	Identification of Human Tumor Antigens by SEREX	49
3.2.2	Specificity of Human Tumor Antigens	50
3.2.2.1	Shared Tumor Antigens	50
3.2.2.2	Differentiation Antigens	51
3.2.2.3	Antigens Encoded by Mutated Genes	51
3.2.2.4	Viral Genes	52
3.2.2.5	Overexpressed Genes	52
3.2.2.6	Amplified Genes	52
3.2.2.7	Splice Variants of Known Genes	52
3.2.2.8	Cancer-related Autoantigens	52
3.2.2.9	Non-cancer-related Autoantigens	52
3.2.2.10	Products of Underexpressed Genes	53
3.2.3	Significance of Antibodies against SEREX Antigens	53
3.2.4	Reverse T Cell Immunology	53
3.2.5	Functional Significance of Human Tumor Antigens	54
3.2.6	The Human Cancer Immunome	54
3.2.7	Perspectives for Vaccine Development	56
3.3	Conclusions	57
	References	58

4 Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part II: Proteomex and AMIDA 63

Barbara Seliger and Olivier Gires

4.1	Introduction	63
4.1.1	A Humoral Response against Self-antigens: The Notion of Tumor-associated Antigens	64

4.2	Implementation of Serum Antibodies: Serological Screening Technologies	65
4.2.1	PROTEOMEX, alias SERPA and SPEARS	66
4.2.1.1	PROTEOMEX Technology and its 'Pros' and 'Cons'	67
4.2.1.2	Candidate Biomarkers Identified by PROTEOMEX	67
4.2.1.3	Implementation of Candidate Biomarkers in the Clinic	68
4.2.2	AMIDA	68
4.2.2.1	Autologous AMIDA	69
4.2.2.2	Allo-AMIDA	69
4.2.3	Advantages and Disadvantages of AMIDA	71
4.3	AMIDA Antigens and Clinical Application	71
4.3.1	Diagnostic TAAs Detected with AMIDA Screening	71
4.3.2	Therapeutic Markers	72
4.4	Conclusions	72
	References	73
5	cDNA and Microarray-based Technologies	79
	<i>Ena Wang, Ping Jin, Hui Lui Liu, David F. Stroncek, and Francesco M. Marincola</i>	
5.1	Introduction	79
5.2	Technical Aspects	80
5.2.1	Handling of Samples and the Need for Consistent Messenger RNA Amplification	81
5.2.1.1	Collection of Source Material and RNA Isolation	82
5.2.1.2	Single Strand cDNA Synthesis	83
5.2.1.3	Double-stranded cDNA (ds-cDNA) Synthesis	84
5.2.2	RNA Amplifications	85
5.2.2.1	Linear Amplification	85
5.2.2.2	PCR-based Exponential Amplification	86
5.2.2.3	Target Labeling for cDNA Microarray using Amplified RNA	88
5.2.2.4	Bioinformatics Tools	89
5.2.2.5	Limitations of Transcriptional Profiling	90
5.2.2.6	Usefulness of Transcriptional Profiling for Antigen Discovery and the Understanding of Tumor–Host Interactions	90
5.3	Summary	93
	References	93
6	Detection and Identification of TAA by SELDI-TOF	103
	<i>Ferdinand von Eggeling and Christian Melle</i>	
6.1	Introduction	103
6.2	SELDI (ProteinChip) Technology	104
6.2.1	The Procedural Method	104
6.2.2	SELDI-MS in TAA Identification	106
6.2.2.1	Tumor Samples	106
6.2.2.2	Body Fluids	106

6.2.2.3	SELDI-MS TAAs and Clinical Potential	107
6.3	Conclusions and Future Perspectives	108
	References	108

Part Three TAAs and Their Usefulness 113

7 Tumor-associated Antigens in Childhood Cancer 115

Uta Behrends and Josef Mautner

7.1	Introduction to Childhood Cancer	115
7.1.1	Incidence, Etiology and Types of Cancer in Children	115
7.1.2	Cure Rates, Treatment Failure and Toxicity	115
7.2	TAA for Pediatric Cancer Therapy	116
7.2.1	Potential Clinical Impact of Childhood TAA and Strategies for their Identification	116
7.2.2	TAA in Childhood Leukemia	117
7.2.3	TAA in Childhood Brain Tumors	119
7.2.4	TAA in Childhood Lymphoma	121
7.2.5	TAA in Pediatric Neuroblastoma	122
7.2.6	TAA in Rhabdomyosarcoma and other Soft Tissue Sarcomas	124
7.2.7	TAA in Osteosarcoma	125
7.2.8	TAA in Tumors of the Ewing Family	126
7.2.9	TAA in Wilms' Tumor	127
7.3	Conclusion	128
	References	129

8 Epigenetically-regulated Therapeutic Tumor-associated Antigens 143

Hugues J. M. Nicolay, Luca Sigalotti, Sandra Coral, Elisabetta Fratta, Alessia Covre, Ester Fonsatti, and Michele Maio

8.1	Introduction	143
8.2	Epigenetics	144
8.2.1	DNA Methylation	144
8.2.2	Histone Post-translational Modifications	145
8.3	TAA	146
8.3.1	Classification of TAA	146
8.3.2	Epigenetically-regulated TAA	146
8.3.2.1	HMW-MAA	146
8.3.2.2	Mucins	147
8.3.2.3	CTA	148
8.4	Perspectives and Conclusion	153
	References	153

9 Cancer Testis Antigens 161

Jonathan Cebon, Otavia Caballero, Thomas John, and Oliver Klein

9.1	Introduction	161
-----	--------------	-----

9.2	Definitions and Classification	162
9.3	Tissue Distribution	163
9.3.1	Normal tissues	163
9.3.2	Tumors	163
9.4	Function	164
9.5	Immunology	166
9.6	Clinical Trials	167
9.7	Conclusions	172
	References	173
10	Rationale for Treatment of Colorectal Cancer with EpCAM Targeting Therapeutics	179
	<i>Patrick A. Baeuerle and Gert Riethmueller</i>	
10.1	Introduction	179
10.2	EpCAM Expression in Colorectal Cancer	181
10.2.1	Frequent and High Level Expression of EpCAM in Primary Tumors of Colon Cancer	181
10.2.2	EpCAM Expression on Colon Cancer Metastases	183
10.2.3	EpCAM Expression on Circulating Colon Cancer Cells	184
10.2.4	EpCAM Expression on Colon Cancer Stem Cells	184
10.2.5	EpCAM Expression on Human Colon Cancer Cell Lines	185
10.3	EpCAM-directed Therapeutic Approaches	185
10.3.1	Clinical Results with Anti-EpCAM Murine Antibody Edrecolomab in Stage II and III CRC	185
10.3.2	Clinical Results with Edrecolomab as a Vaccine for Induction of Anti-idiotypic Response	188
10.3.3	EpCAM Protein as a Vaccine in Colorectal Cancer	189
10.3.4	Adecatumumab, a Novel Fully Human Anti-EpCAM Antibody	190
10.4	Therapeutic Window of EpCAM-directed Therapies	192
10.5	Conclusions	196
	References	198
11	Carcinoembryonic Antigen	201
	<i>Wolfgang Zimmermann and Robert Kammerer</i>	
11.1	CEA Biology	201
11.1.1	CEA Gene Family, Genomic Localization, Protein Structure	201
11.1.2	Evolution	203
11.1.3	Expression	203
11.1.4	Biological Functions	204
11.2	Clinical Relevance of CEA	206
11.2.1	CEA as a Tumor Marker for Prognosis and Post-surgery Follow-up	206
11.2.2	Targeting CEA for Tumor Localization and Therapy	207
11.2.2.1	Animal Models for CEA	207
11.2.2.2	Tumor Localization and Therapy with Anti-CEA Antibodies	207

11.2.2.3	CEA-based Vaccines	209
11.2.3	Immune Monitoring	211
11.3	Conclusion	213
	References	213
12	HER-2 as a Tumor Antigen	219
	<i>Barbara Seliger</i>	
12.1	Introduction	219
12.2	Biology of HER2	219
12.2.1	Features of HER2	219
12.2.2	The Self-antigen HER2 as a Potential Therapeutic Target	220
12.2.3	Determination of HER2 Status in Tumors	222
12.3	General Approaches for Targeting HER2 using Anti-cancer Agents	222
12.4	Active HER2-based Cancer Vaccines	222
12.4.1	HER2-specific Peptides	223
12.4.2	T Cell-mediated Immunity to HER2 in Cancer Patients	224
12.5	Passive Immunotherapy Targeting HER2	224
12.6	HER2 Effects on Immunogenicity: Both Sides of the Coin	225
12.7	Conclusions	226
	References	227
13	Epstein-Barr Virus-associated Antigens	231
	<i>Christoph Mancao and Wolfgang Hammerschmidt</i>	
13.1	Introduction	231
13.2	Functions of EBV Antigens in Latently Infected Cells	232
13.2.1	EBV Nuclear Antigen 1 (EBNA1)	233
13.2.2	EBV Nuclear Antigen 2 and Leader Protein (EBNA2 and EBNA-LP)	233
13.2.3	EBV Nuclear Antigen Family 3 (EBNA3)	234
13.2.4	Latent Membrane Protein 1 (LMP1)	234
13.2.5	Latent Membrane Protein 2 (LMP2)	235
13.3	T-cell Responses to EBV Antigens	236
13.3.1	CD8 ⁺ T-cell Responses	236
13.3.2	CD4 ⁺ T-cell Response	237
13.4	EBV-associated Malignancies	237
13.4.1	Post-Transplant Lymphoproliferative Disease (PTLD)	237
13.4.2	Adoptive T-cell Therapy	238
13.4.3	Burkitt's Lymphoma and Hodgkin's Lymphoma	240
	References	241
14	Human Papillomavirus (HPV) Tumor-associated Antigens	249
	<i>Andreas M. Kaufmann</i>	
14.1	Introduction	249
14.2	HPV-encoded TAA	250
14.2.1	The Proteins of HPV	250
14.2.2	Vaccine Development	253

14.2.3	Therapeutic Vaccine Strategies	253
14.2.4	HPV-induced Cellular TAA	256
14.3	Conclusions and Future Perspectives	256
	References	257
15	Circulating TAAs: Biomarkers for Cancer Diagnosis, CA125	261
	<i>Angela Coliva, Ettore Seregini, and Emilio Bombardieri</i>	
15.1	Introduction	261
15.2	Definition and Classification of Mucins	261
15.3	Structure of MUC 16	263
15.3.1	Gene and Protein Structure	263
15.3.1.1	Domain I	263
15.3.1.2	Domain II	263
15.3.1.3	Domain III	265
15.3.2	Evolutionary Considerations	266
15.4	Distribution of MUC16	266
15.5	MUC16 Function in Normal Tissues	266
15.6	Release of MUC16: CA125 Tumor Marker	267
15.6.1	History	267
15.6.2	Assay Methods	268
15.6.3	Serum CA125 Levels in Healthy Subjects	269
15.6.3.1	Age	269
15.6.3.2	Menstrual cycle	270
15.6.3.3	Pregnancy	270
15.6.3.4	Race	270
15.6.3.5	Other Factors that may affect CA125 Levels	270
15.6.4	Serum CA125 Levels in Patients with Benign Diseases	270
15.6.5	Serum CA125 Levels in Non-ovarian Cancer	270
15.6.6	Serum CA125 Levels in Ovarian Cancers	270
15.7	Clinical Applications	271
15.7.1	Screening	271
15.7.2	Evaluating Pelvic Masses	272
15.7.3	Assessing Prognosis	272
15.7.4	Assessing Response to Therapy	273
15.7.5	Follow-up after Completion of Initial Therapy	274
15.8	Novel Markers	274
15.9	Conclusions	276
	References	276
Part Four	Clinical Applications of TAAs	281
16	Overview of Cancer Vaccines	283
	<i>John Copier and Angus Dalgleish</i>	
16.1	Introduction	283